January Therapeutics today announced the appointment of Dr. Paul Grint to the Board of Directors
Share Article
Dr. Paul Grint is bringing his experience as CMO, CEO (Private & Public Companies), Chairman of the Board, and Board Member to help January s Board SAN DIEGO (PRWEB) May 05, 2021 Dr. Grint has served as the Executive Chairman of the Board of Directors of Cardea Bio since April 2020. He also has served as a member of the Board of Directors and as a member of the compensation committee of Amplyx Pharmaceuticals, Inhibikase Therapeutics and Synedgen.
From 2017 to 2019, Dr. Grint served as Chief Executive Officer of AmpliPhi Biosciences and as a member of AmpliPhi Bioscience’s Board of Directors from 2015 to 2019, additionally from 2014 to 2017 Dr. Grint served as Chief Executive Officer of Regulus Therapeutics, Inc., both publicly traded clinical stage biopharmaceutical companies.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The biosensors market is valued at USD 25.5 billion in 2021 and is projected to reach USD 36.7 billion by 2026; it is expected to grow at a CAGR of 7.5% from 2021 to 2026.
Metal-based nanoparticles can be efficiently used to detect nucleic acid sequences by exploiting their optoelectronic properties. Recent advancements in the field of nanotechnology have led to the utilization of nanomaterials, such as metal nanoparticles, oxide nanoparticles, magnetic nanomaterials, carbon materials, quantum dots, and metallophthalocyanines, to improve the electrochemical signals of biocatalytic events that occur at electrode/electrolyte interface. Nanomaterials, such as carbon nanotubes and indium oxide nanowires, are widely used to manufacture nanotechnology-based biosensors or nanobiosensors. Nanobiosensors have revolutionized the future of disease diagnosis. They are gaining importance in areas such as catalysis, optic
Global Biosensors Market (2021 to 2026) - Increasing Use of Biosensors to Monitor Glucose Levels in Individuals with Diabetes is Driving Growth prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
SNP-Chip: CRISPR-Based Transistor Detects Single Point Mutations SNP-Chip enables amplification-free, electronic, detection of point mutations in DNA from patients with Sickle-Cell Disease and ALS
Long before the COVID-19 pandemic shined a spotlight on CRISPR-based diagnostics, Kiana Aran, PhD, was developing the CRISPR-Chip. It was, according to Aran, the first transistor that uses CRISPR to search the genome for potential mutations. In addition, the graphene field-effect transistor (gFET) did not require amplification or sequencing of the nucleic acid.
Now, two years after its introduction, a group headed by Aran, co-founder and CSO at Cardea Bio, and assistant professor at the Keck Graduate Institute of Applied Life Sciences, is introducing an improved CRISPR-based gFET system, named SNP-Chip.
CRISPR-Chip advance streamlines genetic testing for medical diagnostics and research indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.